Literature DB >> 12356971

Meningitis four years after treatment of macroprolactinoma.

Rachel Wood1, Derek D Sandeman, Mary L Gawne-Cain, Richard I G Holt.   

Abstract

Entities:  

Mesh:

Year:  2002        PMID: 12356971      PMCID: PMC1279176          DOI: 10.1177/014107680209501006

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  5 in total

Review 1.  CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.

Authors:  K S Leong; P M Foy; A C Swift; S L Atkin; D R Hadden; I A MacFarlane
Journal:  Clin Endocrinol (Oxf)       Date:  2000-01       Impact factor: 3.478

2.  Cerebrospinal fluid rhinorrhea and group B streptococcal meningitis.

Authors:  P J Moss; J C Graham; M W McKendrick
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

3.  Giant invasive prolactinoma: a case report and review of nine further cases.

Authors:  J R Davis; M C Sheppard; D A Heath
Journal:  Q J Med       Date:  1990-03

Review 4.  Bromocriptine-induced cerebrospinal fluid fistula in patients with macroprolactinomas: report of three cases and a review of the literature.

Authors:  O Barlas; C Bayindir; K Hepgül; M Can; T Kiriş; E Sencer; F Unal; F Aral
Journal:  Surg Neurol       Date:  1994-06

5.  Cerebrospinal fluid rhinorrhea during treatment with bromocriptine for prolactinoma.

Authors:  J G Kok; A K Bartelink; B P Schulte; A Smals; G Pieters; E Meyer; H Merx
Journal:  Neurology       Date:  1985-08       Impact factor: 9.910

  5 in total
  2 in total

1.  Suppurative meningitis: A life-threatening complication in male macroprolactinomas.

Authors:  Farida Chentli; Lina Akkache; Katia Daffeur; Meriem Haddad; Said Azzoug
Journal:  Indian J Endocrinol Metab       Date:  2013-10

2.  Bacterial meningitis as a first presentation of pituitary macroprolactinoma.

Authors:  Niki Margari; Simon Page
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-05-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.